- Molecular NameIbandronate
- Synonymibandronate; Ibandronate sodium; Ibandronate sodium monohydrate; Ibandronic Acid; R484
- Weight319.231
- Drugbank_IDDB00710
- ACS_NO114084-78-5
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-2.74
- pka2.0
- LogD (pH=7, predicted)-6.85
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)0.5
- LogSw (predicted, AB/LogsW2.0)269.5
- Sw (mg/ml) (predicted, ACD/Labs)191.53
- No.of HBond Donors5
- No.of HBond Acceptors8
- No.of Rotatable Bonds9
- TPSA158.15
- StatusFDA approved
- AdministrationOral, intravenous
- PharmacologyA potent bisphosphonate drug used in the prevention and treatment of osteoporosis.
- Absorption_valueN/A
- Absorption (description)Poorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.
- Caco_2N/A
- Bioavailability1.0
- Protein binding95.2
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmNo evidence of ibandronate being metabolized in humans.
- Half life10~60 h
- ExcretionRenal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySide effects include bronchitis, pneumonia and urinary tract infections.
- LD50 (rat)LD50=811 mg/kg
- LD50 (mouse)N/A